Nature communications · 2024
Reliability of high-quantity human brain organoids for modeling microcephaly, glioma invasion and drug screening.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ramani Anand, Pasquini Giovanni, Gerkau Niklas J, Jadhav Vaibhav, Vinchure Omkar Suhas, Altinisik Nazlican, Windoffer Hannes, Muller Sarah, Rothenaigner Ina, Lin Sean, Mariappan Aruljothi, Rathinam Dhanasekaran, Mirsaidi Ali, Goureau Olivier, Ricci-Vitiani Lucia, D'Alessandris Quintino Giorgio, Wollnik Bernd, Muotri Alysson, Freifeld Limor, Jurisch-Yaksi Nathalie, Pallini Roberto, Rose Christine R, Busskamp Volker, Gabriel Elke, Hadian Kamyar, Gopalakrishnan Jay
Аннотация
Brain organoids offer unprecedented insights into brain development and disease modeling and hold promise for drug screening. Significant hindrances, however, are morphological and cellular heterogeneity, inter-organoid size differences, cellular stress, and poor reproducibility. Here, we describe a method that reproducibly generates thousands of organoids across multiple hiPSC lines. These High Quantity brain organoids (Hi-Q brain organoids) exhibit reproducible cytoarchitecture, cell diversity, and functionality, are free from ectopically active cellular stress pathways, and allow cryopreservation and re-culturing. Patient-derived Hi-Q brain organoids recapitulate distinct forms of developmental defects: primary microcephaly due to a mutation in CDK5RAP2 and progeria-associated defects of Cockayne syndrome. Hi-Q brain organoids displayed a reproducible invasion pattern for a given patient-derived glioma cell line. This enabled a medium-throughput drug screen to identify Selumetinib and Fulvestrant, as inhibitors of glioma invasion in vivo. Thus, the Hi-Q approach can easily be adapted to reliably harness brain organoids' application for personalized neurogenetic disease modeling and drug discovery.